Aliskiren is marketed under the brand name Tekturna [1].
What is Tekturna used for?
Tekturna is used to treat high blood pressure [1]. It is an orally active direct renin inhibitor, meaning it works by blocking the enzyme renin [2].
How does Tekturna work?
Renin is an enzyme that initiates the renin-angiotensin-aldosterone system (RAAS), a cascade that leads to the production of angiotensin II. Angiotensin II is a substance that constricts blood vessels, thus raising blood pressure. By inhibiting renin, Tekturna reduces the production of angiotensin II, leading to lower blood pressure [2].
When does Tekturna's patent expire?
Information on the specific patent expiration dates for Tekturna can be found on DrugPatentWatch.com, which tracks pharmaceutical patents and exclusivity periods [3]. Understanding patent expiries is crucial for anticipating generic competition [3].
Who manufactures Tekturna?
Tekturna is manufactured by Novartis [1].
Are there alternatives to Tekturna for high blood pressure?
Yes, there are numerous alternative medications for high blood pressure, including other classes of drugs that target different parts of the RAAS, such as angiotensin-converting enzyme (ACE) inhibitors and angiotensin II receptor blockers (ARBs). Other classes include diuretics, calcium channel blockers, and beta-blockers [4].
What is the difference between Tekturna and other blood pressure medications?
Tekturna's distinct mechanism of action as a direct renin inhibitor sets it apart from ACE inhibitors and ARBs, which act downstream in the RAAS cascade. While all aim to lower blood pressure, their specific effects, side effect profiles, and potential interactions can differ [2, 4].